Page last updated: 2024-12-10

16,16-dimethylprostaglandin e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You're asking about **16,16-dimethylprostaglandin E₂** (also known as **16,16-dimethyl-PGE₂**). This is a synthetic analog of the naturally occurring prostaglandin E₂ (PGE₂).

**What it is:**

* **Prostaglandins** are a class of lipids that act as powerful signaling molecules in the body. They are involved in a wide range of physiological processes, including inflammation, pain, fever, blood pressure regulation, and reproduction.
* **Prostaglandin E₂ (PGE₂) ** is one of the most studied prostaglandins. It has diverse effects, acting through four different receptor subtypes (EP1-EP4).
* **16,16-dimethyl-PGE₂** is a synthetic analog of PGE₂ that has been modified by adding two methyl groups at the 16th carbon position. This modification changes its properties, making it:
* **More stable:** This means it lasts longer in the body, potentially leading to longer-lasting effects.
* **More potent:** It can activate its receptors more strongly than natural PGE₂.
* **More selective:** It might preferentially activate certain EP receptor subtypes over others.

**Why it's important for research:**

1. **Understanding PGE₂ signaling:** 16,16-dimethyl-PGE₂ serves as a valuable tool for researchers studying the complex actions of PGE₂. By understanding its unique properties and effects, scientists can gain insights into:
* How PGE₂ exerts its diverse physiological functions.
* The specific roles of different EP receptors.
* The potential therapeutic targets for manipulating PGE₂ signaling.

2. **Developing new drugs:** The modified structure of 16,16-dimethyl-PGE₂ has led to its potential as a:
* **Therapeutic agent:** It might be useful in treating various conditions, such as inflammation, pain, and certain types of cancer, by selectively targeting specific EP receptor subtypes.
* **Lead compound:** Its unique properties can serve as a starting point for designing even more potent and selective PGE₂ analogs for drug development.

**Research areas where 16,16-dimethyl-PGE₂ is studied:**

* **Inflammation:** Investigating its role in inflammatory responses and its potential as an anti-inflammatory drug.
* **Pain management:** Exploring its analgesic properties and its potential for treating chronic pain conditions.
* **Cancer:** Studying its effects on tumor growth and angiogenesis (formation of new blood vessels) and its potential as a cancer therapeutic.
* **Reproductive biology:** Examining its role in uterine contractions and its potential applications in reproductive medicine.

**Note:** While 16,16-dimethyl-PGE₂ shows promise in research, it's important to remember that it is still under investigation and has not yet been approved for clinical use.

16,16-dimethylprostaglandin E: RN given refers to (11alpha,13E,15R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283058
CHEBI ID186965
SCHEMBL ID3365336
MeSH IDM0067871

Synonyms (17)

Synonym
16,16-dimethyl-prostaglandin e1
LMFA03010057
9-oxo-11r,15s-dihydroxy-16,16-dimethyl-13e-prostaenoic acid
16,16-dimethyl-pge1
16,16-dimethylprostaglandin e
SCHEMBL3365336
7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]heptanoic acid
41692-15-3
CHEBI:186965
prost-13-en-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (11alpha,13e,15r)-
RQOFITYRYPQNLL-ZWSAOQBFSA-N
HMS3648D15
SR-01000946412-1
sr-01000946412
9-oxo-11alpha,15r- dihydroxy-16,16- dimethyl-prost-13e-en-1-oic acid
PD021160
AKOS040755125

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" It is concluded that cimetidine on this dosage schedule is not effective in the prevention of gastric erosions in a cervical cord section rat model, whereas the ulceroprotective effects of 16,16-dmPGE2 and antacids are significant."( Effects of antacids, cimetidine, and 16,16-dimethyl prostaglandin E2 on acute gastric erosions in a spinal rat.
Gillich, A; Sigman, HH, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (77.78)18.7374
1990's13 (20.63)18.2507
2000's1 (1.59)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.06 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.55%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]